Zedira Transglutaminase Services

Based on our profound expertise in transglutaminase, celiac disease and related fields, Zedira supports your R&D-work on a fee-for-service base.

Service categories include, but are not limited to:

•    Determination of microbial transglutaminase activity in food-preparations
•    Determination of gluten / gliadin content in food and food preparations
•    Production of transglutaminases from animal species (if not already listed in our product catalogue)
•    Modification of transglutaminases (biotin, fluorescent labels, …)
•    Development of transglutaminase assays for customer specific applications
•    Determination of human and animal transglutaminase inhibition in drug development
•    Organic synthesis of small transglutaminase related molecules (e.g. substrates, inhibitors).
    Whatever you need - a product or a service around transglutaminase or related fields, please do not hesitate to contact us.
  Phone:   +49 6151 3251-00
  E-mail:   contact@zedira.com


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation